Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...
08 May, 2026, 10.19 PM IST
'Thank God' Kiran Mazumdar Shaw did not become a doctor: When Dr Devi Shetty shared a life lesson from Biocon founder's inspiring journeyA missed medical college admission propelled Kiran Mazumdar-Shaw towards a different path, ultimately leading to the founding of Biocon. Re...
07 May, 2026, 08.10 AM IST
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
05 May, 2026, 05.35 PM IST
Biocon Biologics expands collaboration with Civica to supply affordable insulin in USBiocon Biologics is expanding its partnership with Civica. This new agreement will bring affordable Insulin Glargine to patients in the Uni...
17 Oct, 2025, 08.27 PM IST
Biocon Biologics gets USFDA nod for diabetes medicationBiocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It...
16 Jul, 2025, 11.07 AM IST
Biocon shares climb 1% on partnership with Civica to boost insulin aspart availability in the USBiocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will supply the insu...
07 Mar, 2025, 09.55 AM IST
Biocon Biologics' arm gets USD 90 mn contract from Malaysian government for supply of insulinsBiocon Biologics, a part of Biocon Ltd, has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to m...
26 Apr, 2022, 10.37 AM IST
Biocon partners with Voluntis to develop digital therapeutics for diabetes patientsThe licensing agreement, signed between Biocon Biologics’ subsidiary Biocon Sdn. Bhd., Malaysia and Voluntis, would make Biocon Biologics o...
21 Jul, 2020, 10.21 AM IST
Biocon, Mylan launch insulin biosimilar in AustraliaThe biotechnology major and pharmaceutical company Mylan N V announced the launch of their insulin biosimilar Semglee.
03 Oct, 2019, 03.18 PM IST
Biocon's Malaysian arm gets EU GMP certification for insulin manufacturing facilityThe integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...
22 Aug, 2019, 03.09 PM IST
Biocon bags Rs 460-crore contract from MalaysiaThe drug, manufactured by Biocon at its large scale biopharmaceutical facility in Johor, Malaysia, is the country's first locally manufactu...
25 Jan, 2017, 12.40 PM IST
European Medicines Agency accepts marketing application of Biocon, Mylan productMylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.
03 Nov, 2016, 08.48 PM IST
US drugmaker Bristol Myers Squibb out of Biocon’s oral insulin projectBMS had taken a wider decision to sell its entire diabetes franchise to British drug maker AstraZeneca, while narrowing its own focus on de...
17 May, 2016, 02.52 AM IST
Biocon links with Mexico's PiSA to tap US insulin marketBiocon said it has entered into a co-development and commercialization alliance with PiSA of Mexico for recombinant human insulin aimed at ...
17 Mar, 2016, 04.40 PM IST
Biocon to further develop insulin TregopilBiocon CMD Kiran Mazumdar-Shaw said: "The data is extremely promising and based on what we know today Tregopil may be positioned as a uniqu...
22 Jan, 2016, 06.55 PM IST
Biocon gets approval for insulin Glargine in MexicoGalactus by PiSA is the first insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, it adde...
09 Apr, 2015, 09.20 PM IST
- Biocon to focus on regional allies for commercialisation
Biocon is altering its product commercialisation strategy by eyeing to partner with many regional players rather than joining hands with a ...
29 Jul, 2012, 01.48 PM IST